A2 Biotherapeutics
AGOURA HILLS, CA · Founded 2017 · CIK 0001828750 · Biotech · Private
CAR-T cell therapy targeting solid tumors
a2bio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $119M
- 2 Form D · Nov 2022
- 47 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 16 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $58,027,099 | |
| Private capital raised | Form D · SEC | $60,855,105 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2809 | Orna Therapeutics Holdings, LLC | — | $121M |
| 2810 | Edgewise Therapeutics | — | $120M |
| 2811 | Ensoma | — | $120M |
| 2812 | A2 Biotherapeutics | — | $119M |
| 2813 | Interius BioTherapeutics | — | $118M |
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Srini AkkarajuDirector
- Madhavan BalachandranDirector
- Scott ForakerDirector · Executive Officer
- Michael GalloDirector
- William GoExecutive Officer
- David GoeddelDirector
- Alexander KambDirector · Executive Officer
- C. KambDirector
- Susan KelleyDirector
- Helen KimDirector
- Thomas LeungExecutive Officer
- Jakob LovenDirector
- David LucasExecutive Officer
Patents
- Engineered Immune Cells With Receptor Cross-talkapplication
- Engineered Immune Cells With Micro-clustersapplication
- Engineered Immune Cells With Receptor Signal Strength Modulated By A Hingeapplication
- Compositions And Methods For Treating Ceacam Positive Cancersapplication
- Gene Fusions For Control Of Genetically Modified Cellsgranted
- Engineered Immune Cells With Micro-clustersgranted
- Compositions And Methods For Treating Blood Cancersapplication
- Engineered Immune Cells With Receptor Cross-talkgranted
- Engineered Immune Cells With Receptor Signal Strength Modulated By A Hingegranted
- Compositions And Methods For Treating Ceacam Positive Cancersgranted
- Compositions And Methods For Treating Mesothelin Positive Cancersapplication
- Engineered Receptors Specific To Hla-e And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.